TechHR
ex
L&D
UNPLUGGED
Sphere
About Us • Contact Us
People Matters Logo
Login / Signup
People Matters Logo
Login / Signup
  • Current
  • Top Stories
  • News
  • Magazine
  • Research
  • Events
  • Videos
  • Webinars
  • Podcast

© Copyright People Matters Media Pte. Ltd. All Rights Reserved.

 

 

  • HotTopic
    LeadersSpeak
  • Strategy
    Leadership Csuite StrategicHR EmployeeRelations
  • Recruitment
    Employer Branding Appointments Permanent Hiring Recruitment
  • Performance
    Skilling PerformanceMgmt Compensation Benefits L&D Employee Engagement
  • Culture
    Culture Life@Work Diversity Watercooler SheMatters
  • Tech
    Technology HR Technology Funding & Investment Startups Metaverse
  • About Us
  • Advertise with us
  • Become a sponsor
  • Contact Us
  • Feedback
  • Submission Guidelines

Follow us:

Privacy Policy • Terms of Use

© Copyright People Matters Media Pte. Ltd. All Rights Reserved.

People Matters Logo
  • Current
  • Top Stories
  • News
  • Magazine
  • Research
  • Events
  • Videos
  • Webinars
  • Podcast
Login / Signup

Categories:

  • HotTopic
    LeadersSpeak
  • Strategy
    Leadership Csuite StrategicHR EmployeeRelations
  • Recruitment
    Employer Branding Appointments Permanent Hiring Recruitment
  • Performance
    Skilling PerformanceMgmt Compensation Benefits L&D Employee Engagement
  • Culture
    Culture Life@Work Diversity Watercooler SheMatters
  • Tech
    Technology HR Technology Funding & Investment Startups Metaverse
Kriya Therapeutics secures $270 million funding; to push for growth acceleration

News • 17th May 2022 • 2 Min Read

Kriya Therapeutics secures $270 million funding; to push for growth acceleration

TechnologyFunding & Investment#Hiring

Author: Ajinkya Salvi Ajinkya Salvi
4.5K Reads
The funding will be utilised to expand teams, advance the gene therapy research and scale its machine-learning based technology.

Kriya Therapeutics has announced that it has secured $270 million in a Series C financing round, led by Patient Square Capital. The latest funding brings the total capital raised by US-based biotech company to about $450 million.

The existing investors who participated included Bluebird Ventures, CAM Capital, Dexcel Pharma, Foresite Capital, JDRF T1D Fund, Lightswitch Capital, Narya Capital, QVT and Transhuman Capital.

The funding will be used to support the advancement of its diverse pipeline and continued scaling of its engineering, manufacturing, and computational platforms, as per the company's statement.

Jim Momtazee, Managing Partner of Patient Square Capital and Kriya Board Member, “Kriya has made tremendous strides over the past few years, attracting world-class talent, expanding its pipeline, and scaling the infrastructure necessary to unlock the full potential of gene therapy. We believe the company has the potential to be the clear leader in the evolving gene therapy field, consistent with Patient Square Capital’s focus to build and support category leading companies in health care.”

The biotech startup, who specialises in gene therapy, was founded in 2019 by Shankar Ramaswamy, Roger Jeffs and John Fraser Wright. For the uninitiated, it billed itself as a next-generation gene therapy company focused on designing & developing treatments for highly prevalent and severe chronic conditions, like diabetes and obesity. Additonally, the company would be expanding their team in the US as well globally. Currently they have 160 employers working tirelessly in labs and offices in the San Francisco Bay Area, USA. 

The biotech startup will also scale its machine learning-enabled technology and cloud computing platform called SIRVE. The platform supports the integration of large datasets generated by the company’s high throughput screening, next generation sequencing, and algorithmic data mining platforms, the company said in its release.

Shankar Ramaswamy, M.D, Co-Founder and Chief Executive Officer, said,“Kriya was founded to address the primary problems limiting the field, and I am proud of the progress we have made to date. This financing will support our continued growth as we advance our diverse pipeline into the clinic and further scale our core platforms, to achieve our ultimate vision of expanding the reach and unlocking the full potential of gene therapy as a modality.

The gene therapy is based on research led by Duke University’s Priya Kishnani, M.D., and Aravind Asokan, Ph.D., and contains five investigational programs for GSDs that have no existing FDA-approved treatments available, yet.

Read More

Did you find this article helpful?


You Might Also Like

New career pathways for Australia’s tech talent

NEWS • 21st Aug 2023 • 3 Min Read

New career pathways for Australia’s tech talent

TechnologyTalent Management#HRCommunity#HRTech
Sam Altman bets on profitable growth of AI

NEWS • 20th Jun 2023 • 2 Min Read

Sam Altman bets on profitable growth of AI

Technology#ArtificialIntelligence
Twitter vs Meta: New CEO ready for battle

NEWS • 24th May 2023 • 1 Min Read

Twitter vs Meta: New CEO ready for battle

Technology
NEXT STORY: Amazon Australia welcomes employees’ dogs into the office

Trending Stories

  • design-thinking-hr

    TikTok's 'MyRTO' app sparks concerns over employee privacy

  • design-thinking-hr

    A change in policy encourages more men to take parental leav...

  • design-thinking-hr

    6 signs your co-worker is gaslighting you

  • design-thinking-hr

    Bad managers raise the risk of office bullying

People Matters Logo

Follow us:

Join our mailing list:

By clicking “Subscribe” button above, you are accepting our Terms & Conditions and Privacy Policy.

Company:

  • About Us
  • Advertise with us
  • Become a sponsor
  • Privacy Policy
  • Terms of Use

Contact:

  • Contact Us
  • Feedback
  • Submission Guidelines

© Copyright People Matters Media Pte. Ltd. All Rights Reserved.

Get the latest Articles, Insight, News & Trends from the world of Talent & Work. Subscribe now!
×

Be Heard: Share Your Feedback and Recommend Our Content!

01
10
Selected Score :
People Matters Logo

Welcome Back!

or

Enter your registered email address to login

Not a user yet? Lets get you signed up!

A 5 digit OTP has been sent to your email address.

This is so we know it's you. Haven't received it yet? Resend the email or then change your email ID.

People Matters Logo

Welcome! Let's get you signed up...

Starting with the absolulte basics.

Already a user? Go ahead and login!

A 5 digit OTP has been sent to your email address.

This is so we know it's you. Haven't received it yet? Resend the email or then change your email ID.

Let's get to know you better

We'll never share your details with anyone, pinky swear.

And lastly...

Your official designation and company name.